Suppr超能文献

[通过都保和雾化器给药的布地奈德]

[Budesonide administered via Turbuhaler and a nebulator].

作者信息

Agertoft L, Pedersen S E

机构信息

Kolding Sygehus, paediatrisk afdeling.

出版信息

Ugeskr Laeger. 1994 Jul 11;156(28):4134-7.

PMID:8066909
Abstract

Two hundred and forty-one children with perennial asthma had their normal dose of budesonide (administered via Nebuhaler) reduced by 50%. Asthma control deteriorated in 126 patients to such an extent that budesonide had to be increased to the normal dose. During a subsequent two week run-in these 126 patients were treated with their normal dose of budesonide via Nebuhaler. Thereafter 64 were randomized to treatment with their normal budesonide therapy and 62 to treatment with half their normal budesonide dose via Turbuhaler for nine weeks. Asthma symptoms, peak-flow measurements, and beta 2-agonist use were recorded. Pulmonary function tests, exercise tests and 24 hour urine sample collections were performed. There were no differences between the groups in any of the parameters studied during run-in or during the study period, except for use of beta 2-agonist, which was significantly lower in the Turbuhaler-treated group. We conclude that Turbuhaler is more effective than Nebuhaler in the treatment of asthma. Therefore the dose of budesonide should be reduced when patients are switched from Nebuhaler to Turbuhaler treatment.

摘要

241名患有常年性哮喘的儿童将其正常剂量的布地奈德(通过都保装置给药)减少了50%。126名患者的哮喘控制恶化到不得不将布地奈德增加至正常剂量的程度。在随后为期两周的导入期,这126名患者通过都保装置接受其正常剂量的布地奈德治疗。此后,64名患者被随机分配接受其正常的布地奈德治疗,62名患者被随机分配通过准纳器接受其正常布地奈德剂量一半的治疗,为期9周。记录哮喘症状、峰值流量测量结果以及β2受体激动剂的使用情况。进行了肺功能测试、运动测试以及24小时尿液样本采集。在导入期或研究期间,除了β2受体激动剂的使用情况外,所研究的任何参数在两组之间均无差异,在准纳器治疗组中β2受体激动剂的使用显著更低。我们得出结论,在哮喘治疗中,准纳器比都保装置更有效。因此,当患者从都保装置治疗转换为准纳器治疗时,布地奈德的剂量应减少。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验